ARS Pharmaceuticals Income Statement (2021-2025) | SPRY

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.66M0.46M0.19M0.02M0.01M0.50M2.07M86.58M7.97M15.72M32.50M
Operating items
Research & Development 5.42M4.35M3.89M4.71M6.55M7.31M3.00M3.40M5.23M6.90M4.42M3.03M2.95M4.04M2.75M
Selling, General & Administrative 2.34M2.46M2.93M10.73M12.18M13.30M14.98M6.82M7.96M8.94M19.28M35.49M41.10M54.31M74.75M
Other Operating Expenses 0.11M0.86M1.09M4.98M8.19M
Operating Expenses 7.76M6.81M6.82M15.44M18.73M20.61M17.98M10.23M13.19M15.84M23.82M39.38M45.15M63.33M85.69M
Operating Income -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
EBIT -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Non-operating items
Other Non Operating Income -0.15M-0.08M0.05M1.15M3.75M3.23M3.11M3.06M2.90M2.82M2.62M3.02M3.24M2.73M2.04M
Non Operating Income -0.15M-0.08M0.05M1.15M3.75M3.23M3.11M3.06M2.90M2.82M2.62M3.02M3.24M2.73M2.04M
Net income details
EBT -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Profit After Tax -7.25M-6.42M-6.58M-14.43M-14.96M-17.37M-14.87M-7.17M-10.29M-12.52M-19.13M49.93M-33.94M-44.88M-51.15M
Income from Continuing Operations -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Consolidated Net Income -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Income towards Parent Company -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Net Income towards Common Stockholders -7.10M-6.34M-6.63M-15.44M-18.71M-20.60M-17.98M-10.23M-13.19M-15.34M-21.75M47.20M-37.18M-47.61M-53.19M
Additional items
EPS (Basic) -0.20-0.18-0.19-0.43-0.20-0.16-0.16-0.07-0.11-0.13-0.200.51-0.35-0.46-0.52
EPS (Weighted Average and Diluted) -0.23-0.21-0.22-0.39-0.20-0.16-0.16-0.07-0.11-0.13-0.200.51-0.35-0.46-0.52
Shares Outstanding (Weighted Average) 34.90M34.91M35.04M35.08M35.14M35.15M35.47M36.06M94.40M94.77M95.57M96.00M96.50M96.90M96.94M97.19M98.12M98.21M98.83M
Shares Outstanding (Diluted Average) 35.00M28.87M30.37M30.61M30.76M39.96M94.23M94.91M95.58M95.22M96.49M96.83M97.03M102.39M98.06M98.36M98.81M
EBITDA -7.25M-6.42M-6.58M-14.02M-15.30M-17.62M-14.85M-6.96M-10.46M-12.54M-18.64M49.81M-34.09M-45.00M-51.11M